The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology. The fourth leading cause of ...

That means Libtayo has a chance to build a position as a go-to immunotherapy in cervical cancer, which is the fourth most commonly occurring cancer in women with around 500,000 cases worldwide ...

or cervical cancer are suitable for treatment with Merck's Keytruda (pembrolizumab) checkpoint inhibitor as well as which patients with NSCLC would benefit from Regeneron's Libtayo (cemiplimab). "With ...

Many types of immunotherapy are being tested in clinical trials, and some are used to treat cervical cancer ... Cemiplimab (Libtayo) also targets PD-1. It can be given to patients with advanced vulvar ...

The risk of recurrence was generally low among cervical cancer patients with no high-risk factors who underwent radical surgery without adjuvant therapy.

At-home screenings are effective alternatives for closing the screening gap. One study found that mailing kits to people ...

The Teal Wand is an at-home vaginal sample self-collection device that tests for HPV. The test will first be available in ...

Teal Health has made an at-home test that screens for human papillomavirus (HPV), the virus that causes nearly all cervical cancers.

To get screened for cervical cancer, patients in the United States may no longer need to put their feet in those awkward ...

Teal Health, the maker of an at-home cervical cancer screening test, says it will give patients an alternative to in-clinic pap smears.

And thanks to a company called Teal Health, that desire may soon be granted: Its at-home, self-collect cervical cancer screening device was approved by the FDA on May 9. It involves running the ...

The U.S. Food and Drug Administration has approved the first at-home test for cervical cancer screening, its maker Teal ...